- Reuters•37 minutes ago
Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival. Given earlier impressive clinical trial results, investors expect the Food and Drug Administration (FDA) to clear both Roche's multiple sclerosis (MS) treatment Ocrevus and Sanofi's new eczema drug Dupixent.
- Zacks•22 hours ago
Value investing is easily one of the most popular ways to find great stocks in any market environment.
- PR Newswire•yesterday
Sanofi Genzyme Extends its Multiple Myeloma Journey Partners Program to Cities Nationwide to Help Improve Patient Outcomes through Peer-to-Peer Education
CAMBRIDGE, Mass., March 22, 2017 /PRNewswire/ -- Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the extension of the Multiple Myeloma Journey Partners Program that leverages storytelling as a tool to improve the patient experience with multiple myeloma. Journey Partners are multiple myeloma patients that have experienced similar emotions, faced the same challenges and asked the same questions about living with the disease. "Sanofi Genzyme created the Multiple Myeloma Journey Partners Program to let multiple myeloma patients know they are not alone and to provide educational resources and services that help patients and families navigate their journey to achieve the best possible outcomes," says Bhavesh Ashar, Vice President and General Manager of US Oncology, Sanofi Genzyme.
SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance
NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
|Bid||44.34 x 100|
|Ask||45.50 x 1000|
|Day's Range||44.55 - 44.88|
|52 Week Range||36.81 - 45.07|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.09|
|Dividend & Yield||1.58 (3.56%)|
|1y Target Est||N/A|